Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials

The Lancet. Diabetes & Endocrinology
Jacob A UdellBenjamin M Scirica

Abstract

Some glucose-lowering drugs or strategies adversely affect cardiovascular outcomes. We aimed to assess the extent to which glucose lowering by various drugs or strategies increases the risk of heart failure in patients with or at risk for type 2 diabetes, and to establish whether risk is associated with achieved differences in glycaemia or weight control. We searched Ovid Medline, the Cochrane Library, and meeting abstracts up to Feb 20, 2015, for large randomised controlled trials of glucose-lowering drugs or strategies that assessed cardiovascular outcomes. The primary endpoint was incidence of heart failure. We derived pooled risk ratios (RRs) with random-effects models. We included data from 14 trials, with mean duration 4·3 (2·3) years, comprising 95 502 patients, of whom 3907 (4%) patients developed a heart failure event. Glucose-lowering drugs or strategies were associated with a 0·50% (SD 0·33) reduction in HbA1c and a 1·7 kg (2·8) weight gain. Overall, glucose-lowering drugs or strategies increased the risk of heart failure compared with standard care (RR 1·14, 95% CI 1·01-1·30; p=0·041). The magnitude of this effect varied dependent on the method of glucose lowering (p for interaction=0·00021). Across drug classes, ri...Continue Reading

References

Jul 1, 1974·The American Journal of Cardiology·W B KannelW P Castelli
Jun 8, 2001·Circulation·C IribarrenJ V Selby
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
Jan 25, 2003·BMJ : British Medical Journal·Douglas G Altman, J Martin Bland
Jul 24, 2003·JAMA : the Journal of the American Medical Association·Jean-Louis ChiassonUNKNOWN STOP-NIDDM Trial Research Group
Jul 28, 2004·Diabetes Care·Gregory A NicholsJonathan B Brown
Mar 1, 2005·Diabetes Care·Christopher Nielson, Theodore Lange
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
Jan 24, 2007·Lancet·Lars RydénKarl Swedberg
Mar 7, 2007·Circulation·C HeldUNKNOWN ONTARGET/TRANSCEND Investigators
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Jul 22, 2009·Annals of Internal Medicine·Tanika N KellyJiang He
Mar 17, 2010·The New England Journal of Medicine·Rury R HolmanRobert M Califf
Mar 4, 2011·The New England Journal of Medicine·Sreenivasa Rao Kondapally SeshasaiUNKNOWN Emerging Risk Factors Collaboration
May 6, 2011·Diabetes Care·Bernd Stratmann, Diethelm Tschoepe
Jul 26, 2011·BMJ : British Medical Journal·Jonathan A C SterneJulian P T Higgins
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Apr 1, 2014·JAMA : the Journal of the American Medical Association·A Michael LincoffUNKNOWN AleCardio Investigators
Apr 16, 2014·The Lancet. Diabetes & Endocrinology·John J V McMurrayMarc A Pfeffer
May 6, 2014·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·M MonamiE Mannucci
Jul 7, 2014·JACC. Heart Failure·Deepak L Bhatt, Matthew A Cavender
Sep 6, 2014·Circulation·Gregg C Fonarow

❮ Previous
Next ❯

Citations

Nov 3, 2015·The American Journal of Medicine·Matthew A CavenderDeepak L Bhatt
Sep 29, 2015·Trends in Cardiovascular Medicine·Sanam Lathief, Silvio E Inzucchi
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Dec 15, 2015·Canadian Journal of Diabetes·David Fitchett
Jul 25, 2015·Diabetic Medicine : a Journal of the British Diabetic Association·D T EurichF A McAlister
Apr 4, 2016·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Bruce A PerkinsDavid Z I Cherney
Jul 15, 2015·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·B A KappelM Federici
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Mar 21, 2015·The Lancet. Diabetes & Endocrinology·Iwan C C van der Horst, Frederik Keus
May 25, 2016·The Lancet. Diabetes & Endocrinology·Jack R W BrownriggRobert J Hinchliffe
Sep 23, 2016·European Journal of Heart Failure·David H FitchettSilvio E Inzucchi
Oct 8, 2016·Cardiovascular Diabetology·Oliver SchnellUNKNOWN D&CVD EASD Study Group
Mar 27, 2016·The Lancet. Diabetes & Endocrinology·Abhinav SharmaRobert J Mentz
Oct 21, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Bhavana SosaleArpandev Bhattacharyya
Jan 15, 2017·Cardiovascular Diabetology·Jason Kar Sheng LewRajesh Katare
Nov 16, 2016·Journal of Clinical Epidemiology·Tobias BluhmkiJan Beyersmann
May 20, 2017·Current Treatment Options in Cardiovascular Medicine·Katie M Murphy, Julie L Rosenthal
May 21, 2017·The American Journal of Medicine·Francesco Paneni, Thomas F Lüscher
Feb 17, 2017·Cardiovascular Research·Christoph Maack, Elizabeth Murphy
Dec 14, 2016·Clinical Medicine : Journal of the Royal College of Physicians of London·Paul D Callan, Andrew L Clark
Jul 4, 2017·Expert Opinion on Pharmacotherapy·Alexandra Sophie MossGregory Y H Lip
Mar 24, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Ildiko Lingvay
Jul 8, 2017·Expert Opinion on Pharmacotherapy·Niki KatsikiDimitri P Mikhailidis
Jun 26, 2017·Current Heart Failure Reports·Frederik H Verbrugge
Dec 19, 2017·European Journal of Heart Failure·Angelo Avogaro
Aug 25, 2017·European Journal of Heart Failure·Javed ButlerUNKNOWN EMPEROR Trials Program
Apr 2, 2016·Therapeutic Advances in Drug Safety·Thomas KaragiannisApostolos Tsapas
Oct 11, 2017·Cardiovascular Research·Edoardo BerteroChristoph Maack
Jul 12, 2018·Journal of Cellular and Molecular Medicine·Hailong ZhangYuanfang Ma
Apr 21, 2017·Journal of the American Heart Association·Christianne L RoumieMarie R Griffin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.